Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05216068
Other study ID # CMRPG8M0241
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 1, 2021
Est. completion date December 31, 2024

Study information

Verified date February 2024
Source Chang Gung Memorial Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Blastocysts derived from patients seeking infertility treatment were generated by in vitro fertilization and embryo culture as previously described, and were evaluated using the Gardner system. As part of the embryo selection process, cells of TE biopsy were collected, and blastocysts were vitrified. The clinical TE biopsies were subjected to whole genome amplification (WGA) with SurePlex reagents (Illumina) followed by NGS-based PGT-A using Illumina's VeriSeq kit (Illumina) on a MiSeq system (Illumina) according to the manufacturer's protocol.


Description:

Collected 200 donate abandonment embryos (well-developed blastocysts) for research under the National Assisted Reproduction Act of Taiwan. 1. Collected 200 donate abandonment embryos: Five to six days after egg retrieval, well-developed embryos (called blastocysts). 2. Blastocysts derived from patients seeking infertility treatment were generated. 3. Embryos biopsies for PGT-A (by use of NGS platforms from our institute) will be used for the validation of our Lab QC embryo. 4. To standardize the operating procedures 5. Paper writing.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date December 31, 2024
Est. primary completion date November 30, 2024
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 50 Years
Eligibility Inclusion Criteria: - the surplus blastocysts - parents consent to donate the embryos Exclusion Criteria: - not agree to participate in this program - whose embryo morphology and quality do not meet the technical requirements for genetic testing

Study Design


Intervention

Diagnostic Test:
NGS
Based on the next generation sequencing (NGS), WES can identify single nucleotide variants (SNVs) and small variants.

Locations

Country Name City State
Taiwan Chang Gung Memorial Hospital Kaohsiung

Sponsors (1)

Lead Sponsor Collaborator
Chang Gung Memorial Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Blastocyst aneuploidy rate anormal Karyotype according to human genome 19 or updated version 28 days
Secondary Whole genome amplification rate success rate 7 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01419392 - Role of Sildenafil Citrate in Patients With Unexplained Recurrent Miscarriages Phase 4
Completed NCT00193674 - Habitual Abortion Study: Oral Dydrogesterone Treatment During Pregnancy in Women With Recurrent Miscarriage Phase 3
Completed NCT06001060 - Distinct Alterations in Gut Microbiota Composition Among Women of Reproductive Age With Elevated Homocysteine Levels.
Recruiting NCT05034250 - Iron Status in Female Infertility and Recurrent Miscarriage
Completed NCT02681627 - Sim (Scratch in Miscarriage) Study N/A
Recruiting NCT02303171 - Use of Warfarin After the First Trimester in Pregnant Women With APS Phase 4
Completed NCT02305420 - EmbryoGen/ Blastgen for Couples With Implantation Problems or Previous Miscarriage Phase 4
Recruiting NCT05824897 - The Cohort Study of the Correlation Between Serum 25(OH)D Level and Pregnancy Outcome
Completed NCT03023137 - Walking and Dietary Modification for Recurrent Early Miscarriages N/A
Not yet recruiting NCT03132779 - Intralipid Related Effect on NKcells in Patients With Unexplained Recurrent Spontaneous Abortion Phase 1
Completed NCT02184741 - A Study of the Efficacy and Safety of GB-0998 in Patients With Unexplained Recurrent Miscarriage Phase 3
Active, not recruiting NCT02156063 - A Multi-center, Placebo-controlled Study to Evaluate NT100 in Pregnant Women With a History of Unexplained Recurrent Pregnancy Loss (RPL) Phase 2
Recruiting NCT03902912 - Effect of Prednisolone Treatment on Uterine Natural Killer Cells Phase 3
Not yet recruiting NCT03209063 - The Role of Prothrombin Gene and Methylenetetrahydrofolate Reductase(MTHFR) Gene Polymorphisms as Risk Factors for Recurrent Miscarriage
Completed NCT03970954 - Low-dose Interleukin-2 in Women With Unexplained Miscarriages Phase 1/Phase 2
Not yet recruiting NCT06249230 - The Analysis of Risk Factors for Recurrent Pregnancy Loss and Prediction of Pregnancy Loss Risk
Recruiting NCT05725512 - Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages Phase 4
Recruiting NCT05267678 - Nutritional Deficiency and Recurrent Miscarriage
Completed NCT02694367 - Expression of EPK in Recurrent Miscarriage N/A
Completed NCT02504281 - Study on the Association Between SXCI and RM and the Possible Genetic Mechanism